Eads & Heald Wealth Management Makes New $854,000 Investment in Gilead Sciences, Inc. $GILD

Eads & Heald Wealth Management bought a new stake in Gilead Sciences, Inc. (NASDAQ:GILD) in the 1st quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor bought 6,128 shares of the biopharmaceutical company’s stock, valued at approximately $854,000.

A number of other hedge funds and other institutional investors have also modified their holdings of the stock. Strategic Investment Solutions Inc. IL purchased a new stake in shares of Gilead Sciences in the fourth quarter valued at about $25,000. Vermillion & White Wealth Management Group LLC raised its stake in Gilead Sciences by 71.4% during the fourth quarter. Vermillion & White Wealth Management Group LLC now owns 204 shares of the biopharmaceutical company’s stock worth $25,000 after purchasing an additional 85 shares during the period. Quattro Advisors LLC acquired a new position in Gilead Sciences in the 4th quarter valued at about $26,000. Wealth Preservation Advisors LLC boosted its holdings in Gilead Sciences by 60.0% in the 4th quarter. Wealth Preservation Advisors LLC now owns 216 shares of the biopharmaceutical company’s stock valued at $27,000 after purchasing an additional 81 shares during the last quarter. Finally, Ares Financial Consulting LLC purchased a new stake in shares of Gilead Sciences in the 4th quarter valued at approximately $28,000. 83.67% of the stock is owned by institutional investors and hedge funds.

Gilead Sciences Price Performance

Shares of GILD opened at $136.36 on Wednesday. The company has a quick ratio of 1.77, a current ratio of 1.97 and a debt-to-equity ratio of 0.89. Gilead Sciences, Inc. has a fifty-two week low of $107.75 and a fifty-two week high of $157.29. The company has a market cap of $169.30 billion, a P/E ratio of 18.58 and a beta of 0.32. The firm’s 50 day moving average price is $129.48 and its 200 day moving average price is $134.82.

Gilead Sciences (NASDAQ:GILD) last posted its quarterly earnings results on Thursday, May 7th. The biopharmaceutical company reported $2.03 EPS for the quarter, topping the consensus estimate of $1.91 by $0.12. The business had revenue of $6.96 billion during the quarter, compared to the consensus estimate of $6.91 billion. Gilead Sciences had a net margin of 30.99% and a return on equity of 48.19%. The company’s quarterly revenue was up 4.4% compared to the same quarter last year. During the same quarter in the previous year, the firm posted $1.81 earnings per share. Gilead Sciences has set its FY 2026 guidance at -1.050–0.650 EPS. On average, research analysts forecast that Gilead Sciences, Inc. will post -0.8 earnings per share for the current fiscal year.

Gilead Sciences Dividend Announcement

The business also recently declared a quarterly dividend, which was paid on Monday, June 29th. Shareholders of record on Monday, June 15th were issued a dividend of $0.82 per share. The ex-dividend date was Monday, June 15th. This represents a $3.28 annualized dividend and a yield of 2.4%. Gilead Sciences’s dividend payout ratio is 44.69%.

Gilead Sciences News Roundup

Here are the key news stories impacting Gilead Sciences this week:

• Positive Sentiment: Gilead won FDA approval to expand Trodelvy into first-line metastatic triple-negative breast cancer, a meaningful label expansion that could broaden the drug’s market opportunity and strengthen the company’s oncology growth story. Will the Label Expansion of Trodelvy Strengthen GILD’s Oncology Portfolio?
• Positive Sentiment: HSBC upgraded Gilead to Buy and raised its price target to $155, citing continued upside from long-acting HIV treatments and oncology assets. Generic Fears Overdone? Gilead Stock Has More Room to Run, Analyst Says
• Positive Sentiment: Cantor Fitzgerald reaffirmed an Overweight rating and kept a $155 price target, signaling confidence in Gilead’s earnings and pipeline outlook. Read More
• Positive Sentiment: Broader biotech sentiment also looked favorable after Jim Cramer called biotech “the hottest group in the market” and said a wave of M&A could be coming, which can lift names like Gilead. Jim Cramer Calls Biotech “The Hottest Group in the Market” as He Predicts “Deals Are Going to Be Flooding the Market”
• Neutral Sentiment: Royal Bank of Canada trimmed its price target to $120 from $122 and kept a Sector Perform rating, which is a modestly cautious view but not a major negative catalyst. Read More
• Neutral Sentiment: Gilead’s stock also drew attention from market commentary noting the shares had run up sharply and were trading well above GuruFocus’ GF Value estimate, suggesting valuation may be getting stretched. A Look at Gilead Sciences Inc (GILD) After 5.2% Gain — GF Value $96.06 vs Price $136.36

Analyst Ratings Changes

Several analysts have recently commented on GILD shares. Citigroup lifted their price target on shares of Gilead Sciences from $156.00 to $165.00 and gave the company a “buy” rating in a research report on Monday, April 13th. Royal Bank Of Canada cut their target price on Gilead Sciences from $122.00 to $120.00 and set a “sector perform” rating for the company in a research note on Tuesday. Cantor Fitzgerald restated an “overweight” rating and issued a $155.00 target price on shares of Gilead Sciences in a research report on Monday. Maxim Group raised Gilead Sciences from a “hold” rating to a “buy” rating and set a $165.00 price target on the stock in a research note on Wednesday, May 20th. Finally, Daiwa Securities Group lowered their price target on Gilead Sciences from $161.00 to $150.00 and set an “outperform” rating for the company in a report on Tuesday, May 19th. Twenty-six equities research analysts have rated the stock with a Buy rating and three have assigned a Hold rating to the company. Based on data from MarketBeat.com, the company has an average rating of “Moderate Buy” and a consensus target price of $159.11.

Insider Buying and Selling at Gilead Sciences

In related news, insider Johanna Mercier sold 3,000 shares of the company’s stock in a transaction that occurred on Monday, June 15th. The shares were sold at an average price of $123.92, for a total transaction of $371,760.00. Following the sale, the insider directly owned 124,234 shares in the company, valued at approximately $15,395,077.28. This represents a 2.36% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CFO Andrew D. Dickinson sold 3,000 shares of Gilead Sciences stock in a transaction that occurred on Monday, June 15th. The stock was sold at an average price of $125.40, for a total transaction of $376,200.00. Following the completion of the transaction, the chief financial officer owned 171,646 shares of the company’s stock, valued at $21,524,408.40. This represents a 1.72% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold 83,000 shares of company stock valued at $10,824,500 in the last quarter. Corporate insiders own 0.30% of the company’s stock.

Gilead Sciences Company Profile

Gilead Sciences, Inc, founded in 1987 and headquartered in Foster City, California, is a biopharmaceutical company focused on the discovery, development and commercialization of medicines in areas of high unmet medical need. The company initially built its reputation in antiviral therapies and has since expanded into oncology, cell therapy and inflammatory diseases. Gilead operates a global research and commercial organization, conducting clinical development and selling medicines in markets around the world.

Gilead’s product portfolio is anchored by antiviral therapies for HIV and viral hepatitis.